Accuray Incorporated

Accuray Incorporated has been granted 121 US utility patents between 2015 and 2025, placing Accuray Incorporated at rank #3,111 across all assignees tracked by PlainPatent. This portfolio spans 20 distinct Cooperative Patent Classification (CPC) subclasses, averaging 20.2 claims per patent with primary concentration in A61N (ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY). As a US Corporation, Accuray Incorporated is one of the more focused assignees in the PatentsView dataset. The composite Innovation Score of 52.6/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 79 grants, compared with 42 in the 2015–2019 window — a +88% shift in five-year velocity. An acceleration of this magnitude signals aggressive R&D investment and expanding technical ambition. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. Accuray Incorporated's 20.2 average claims per patent reflects complex, broadly scoped inventions that are difficult for competitors to design around, while a multi-domain presence across 20 subclasses balances depth with breadth. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Accuray Incorporated against peers pursuing similar technology classes.